Search

Displaying results 1381 - 1390 of 7538 in total
  1. Drug

    Carindacillin

    go.drugbank.com/drugs/DB09319
    ApprovedWithdrawn

    Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of [carbenicillin] marketed by Pfizer as Geocillin. It is no longer marketed in the United States.

  2. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements … Mafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.

  3. Drug

    Clomifene

    go.drugbank.com/drugs/DB00882
    ApprovedInvestigational

    A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.

    Synonyms: 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine
  4. Drug

    Insulin human

    go.drugbank.com/drugs/DB00030
    ApprovedInvestigational

    cells that the body is no longer able to produce insulin on its own. … Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin.

    Products: Humulin N, Novolin N
  5. Drug

    Verteporfin

    go.drugbank.com/drugs/DB00460
    ApprovedInvestigational

    Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet … oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

  6. Drug

    Midazolam

    go.drugbank.com/drugs/DB00683
    ApprovedIllicitInvestigational

    [F2977] This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. … [L45098] In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults.

    Products: N/a
  7. Drug

    Atracurium besylate

    go.drugbank.com/drugs/DB00732
    Approved

    A non-depolarizing neuromuscular blocking agent with short duration of action. … Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents

  8. Drug

    Levamlodipine

    go.drugbank.com/drugs/DB09237
    ApprovedInvestigational

    [L10833] As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. … [A188940] Levamlodipine was granted FDA approval on 19 December 2019.[L10833]

  9. Drug

    Pivhydrazine

    go.drugbank.com/drugs/DB09252
    ApprovedWithdrawn

    In 1960, it was widely used as an antidepressant agent but it is now discontinued. … Pivhydrazine, also known as pivazide, is a member of the hydrazine family with irreversible and non-selective inhibitory activity against monoamine oxidases.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. … [L4563] In particular, cenegermin was granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing where the agency determines